Although preclinical models demonstrated robust efficacy of ROR1-directed CAR-T cells in eliminating NSCLC organoids, clinical translation was limited by insufficient persistence and heterogeneous antigen expression (78). Here, ROR1 is linked to non-small cell lung carcinoma.